Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 270 of 270 entries
View as:

Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live, Cold-Adapted (CAIV-T) in Healthy Children

Phase: N/A Priority: Normal
NCT ID: NCT00192244 Org: User:
Start: 09/30/00 End: 10/31/02 Due: 10/31/03

A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma

Phase: N/A Priority: Normal
NCT ID: NCT00507130 Org: User:
Start: 07/31/07 End: 09/30/08 Due: 09/30/09

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season

Phase: N/A Priority: Normal
NCT ID: NCT03158038 Org: User:
Start: 05/30/17 End: 12/14/17 Due: 12/14/18

Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT02151110 Org: User:
Start: 05/27/14 End: 05/09/16 Due: 05/09/17

A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Phase: N/A Priority: Normal
NCT ID: NCT01466153 Org: User:
Start: 02/07/12 End: 01/08/16 Due: 01/08/17

Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older

Phase: N/A Priority: Normal
NCT ID: NCT00217230 Org: User:
Start: 04/30/01 End: 11/30/01 Due: 11/30/02

A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02556463 Org: User:
Start: 11/04/15 End: 10/26/18 Due: 10/26/19

A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03889275 Org: User:
Start: 10/24/19 End: 12/12/22 Due: 12/12/23

A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis

Phase: N/A Priority: Normal
NCT ID: NCT00979654 Org: User:
Start: 08/31/10 End: 03/31/15 Due: 03/31/16

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03794544 Org: User:
Start: 03/08/19 End: 01/13/21 Due: 01/13/22

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children

Phase: N/A Priority: Normal
NCT ID: NCT00192322 Org: User:
Start: 09/30/01 End: 12/31/01 Due: 12/31/02

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT02114268 Org: User:
Start: 04/30/14 End: 06/30/15 Due: 06/30/16

Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00081315 Org: User:
Start: 11/30/03 End: 08/31/06 Due: 08/31/07

Study to Evaluate MEDI-534 in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT00111878 Org: User:
Start: 04/30/05 End: 12/31/05 Due: 12/31/06

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02261220 Org: User:
Start: 10/13/14 End: 01/27/20 Due: 01/27/21

A Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose for MEDI-545

Phase: N/A Priority: Normal
NCT ID: NCT00472758 Org: User:
Start: 02/28/07 End: 03/31/08 Due: 03/31/09

Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza

Phase: N/A Priority: Normal
NCT ID: NCT03903718 Org: User:
Start: 04/03/20 End: 10/09/20 Due: 10/09/21

A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants

Phase: N/A Priority: Normal
NCT ID: NCT00686075 Org: User:
Start: 06/30/08 End: 08/31/12 Due: 08/31/13

Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease

Phase: N/A Priority: Normal
NCT ID: NCT03004638 Org: User:
Start: 01/23/17 End: 11/02/17 Due: 11/02/18

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)

Phase: N/A Priority: Normal
NCT ID: NCT00192231 Org: User:
Start: 04/30/01 End: 06/30/01 Due: 06/30/02